R3X1 Stock Overview
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ocuphire Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$6.01 |
| 52 Week Low | US$1.39 |
| Beta | 0.24 |
| 1 Month Change | -20.78% |
| 3 Month Change | -40.37% |
| 1 Year Change | -68.78% |
| 3 Year Change | -64.12% |
| 5 Year Change | n/a |
| Change since IPO | -61.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| R3X1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | 2.3% | 0.5% |
| 1Y | -68.8% | -28.6% | 1.3% |
Return vs Industry: R3X1 underperformed the German Pharmaceuticals industry which returned -28.6% over the past year.
Return vs Market: R3X1 underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| R3X1 volatility | |
|---|---|
| R3X1 Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R3X1's share price has been volatile over the past 3 months.
Volatility Over Time: R3X1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 14 | George Magrath | www.ocuphire.com |
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
Ocuphire Pharma, Inc. Fundamentals Summary
| R3X1 fundamental statistics | |
|---|---|
| Market cap | €35.61m |
| Earnings (TTM) | -€9.33m |
| Revenue (TTM) | €17.81m |
2.1x
P/S Ratio-4.0x
P/E RatioIs R3X1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R3X1 income statement (TTM) | |
|---|---|
| Revenue | US$19.05m |
| Cost of Revenue | US$1.08m |
| Gross Profit | US$17.97m |
| Other Expenses | US$27.96m |
| Earnings | -US$9.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 94.36% |
| Net Profit Margin | -52.42% |
| Debt/Equity Ratio | 0% |
How did R3X1 perform over the long term?
See historical performance and comparison